AbbVie has 45 disclosed EU lobbying meetings from 2024-10-17 to 2026-06-04: 2 with the European Commission and 43 with Members of the European Parliament. Source: EU Transparency Register no. 934069612666-51, Commission disclosures and MEP declarations. Methodology
AbbVie
EU lobbying footprint — who they meet, and on what.
- Register no.
- 934069612666-51 ↗
- Disclosed meetings
- 45 (2 Commission · 43 MEP)
- Period
- 2024-10-17 → 2026-06-04
Declared fields of interest: Business and industry · Competition · Digital economy and society · Economy, finance and the euro · Employment and social affairs · Institutional affairs · Public health · Research and innovation · Single market · Trade
Lobbying profile
as declared 2026-03-06- Category
- Companies & groups
- Legal status
- AbbVie inc.
- Declared lobbying cost
- €1,000,000
- Lobbying FTEs
- 2.45
- Members
- 2
At a glance
- Health1
- Chiara Galiffa1
- Carmen Laplaza Santos1
Disclosed meetings
Newest first. EC = European Commission, EP = Member of the European Parliament.
- Strengthening Europe's Biotech Ecosystemsource ↗
- Meeting on EU health policysource ↗
- healthcaresource ↗
- 2026-05-07ECChiara Galiffa · Cabinet of Commissioner Maroš ŠefčovičLatest developments in EU-US relationssource ↗
- EU Biotech Act Isource ↗
- Follow-Up Discussion on the Critical Medicines Actsource ↗
- SANT COMMITTEE ONGOING WORKsource ↗
- Health policysource ↗
- Biotechsource ↗
- Innovación sanitaria en Europasource ↗
- 2026-02-03ECCarmen Laplaza Santos · Head of UnitExchange of views on the competitiveness of the European pharmaceutical sector.source ↗
- Standortbesuchsource ↗
- Critical Medicines Actsource ↗
- Meeting about Critical Medicines Act and Biotech Actsource ↗
- Politischer Austausch zur UWWTDsource ↗
- Pharma packagesource ↗
- CMA and Biotech Actsource ↗
- EU initiatives in healthsource ↗
- Biotech Actsource ↗
- Biotech Actsource ↗
- Health Policiessource ↗
- Competitiveness, innovation, incl. Biotech Actsource ↗
- Critical Medicines Actsource ↗
- Pharmaceuticalssource ↗
- Pharmaceuticalssource ↗
- CMAsource ↗
- Tematiche salutesource ↗
- Trade Policy & Health Policysource ↗
- Pharma Packagesource ↗
- Discussion on Critical Medicines Act amendmentssource ↗
- CMAsource ↗
- Critical medicines actsource ↗
- Health policysource ↗
- Health Policysource ↗
- Parkinson’s care in Europesource ↗
- Critical Medicines Actsource ↗
- Migraine and women's healthsource ↗
- Critical Medicines Act, Pharma legislation, trade, BioTech Actsource ↗
- Introductory Meetingsource ↗
- Introductory Meetingsource ↗
- Herzgesundheitsource ↗
- Women's Health and Unmet Medical Needs – Migraine, Menopause, and Other Challengessource ↗
- Innovative Solutions to the European Health Systemssource ↗
- European health policysource ↗
- Health policysource ↗
Lobbying in these areas
Frequently asked
How many EU lobbying meetings has AbbVie disclosed?
AbbVie (EU Transparency Register no. 934069612666-51) appears in 45 disclosed meetings with EU officials and MEPs between 2024-10-17 and 2026-06-04: 2 with the European Commission and 43 with Members of the European Parliament.
What does AbbVie lobby on?
AbbVie's disclosed EU meetings most often concern Health. Every meeting and its topic is listed with its official source on this page.
Who does AbbVie meet in Brussels?
Across its disclosed meetings, AbbVie has met Commission officials including Chiara Galiffa, Carmen Laplaza Santos, and MEPs including VERYGA Aurelijus, SOKOL Tomislav, DE LA PISA CARRIÓN Margarita. These are counts of officially disclosed meetings, not a measure of influence.
Primary sources
- EU Transparency Register profile (no. 934069612666-51) ↗
- European Commission meeting disclosures ↗
- European Parliament — MEP meeting declarations ↗
Every meeting above is a public disclosure by the European Commission or a Member of the European Parliament; counts are of disclosed meetings only and are not a measure of influence. Methodology. Data © European Union (Decision 2011/833/EU) & the European Parliament.
Get the EU lobbying brief
We’ll email you when major new lobbying meetings are disclosed — free, no account, built from public EU data with every entry cited. We only email on real updates.